Search Clinical Trials
Sponsor Condition of Interest |
---|
Avatrombopag vs. Placebo for CIT in GI Malignancies
Hanny Al-Samkari, MD
Gastrointestinal Cancer
Gastrointestinal Neoplasms
Chemotherapy-Induced Thrombocytopenia
The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag
versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in
patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy.
The names of the study drugs involved in this... expand
The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. The names of the study drugs involved in this study are: - Avatrombopag (a thrombopoietin receptor agonist) - Matching placebo Type: Interventional Start Date: Nov 2023 |
Study of Tecovirimat for Human Mpox Virus
National Institute of Allergy and Infectious Diseases (NIAID)
MPOX
A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy
of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV
disease. expand
A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV disease. Type: Interventional Start Date: Sep 2022 |
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants...
ModernaTX, Inc.
Advanced Solid Tumors
The primary goal of this study is to assess the safety and tolerability of mRNA-4359
administered alone and in combination with pembrolizumab. expand
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab. Type: Interventional Start Date: Aug 2022 |
MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study
Microvention-Terumo, Inc.
Intracranial Aneurysm
The objective of this study is to generate contemporaneous clinical data to facilitate a
reasonable comparison of the performance of the FRED™ X™ device with the performance of
the FRED™ device. The data generated from this study will be compared to the safety and
effectiveness of the FRED™ device... expand
The objective of this study is to generate contemporaneous clinical data to facilitate a reasonable comparison of the performance of the FRED™ X™ device with the performance of the FRED™ device. The data generated from this study will be compared to the safety and effectiveness of the FRED™ device by meeting the same performance goals (PGs) established for the FRED™ pivotal study. Type: Interventional Start Date: Sep 2022 |
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
Shayna Sarosiek, MD
IgM MGUS
Waldenstrom Macroglobulinemia
Neuropathy;Peripheral
In this research study, is combining a new treatment acalabrutinib with a standard
treatment, rituximab or other CD20 antibody, to determine whether this combination is
safe and effective for participants with Immunoglobulin (Ig) M monoclonal gammopathy of
undetermined significance ( IgM MGUS) or... expand
In this research study, is combining a new treatment acalabrutinib with a standard treatment, rituximab or other CD20 antibody, to determine whether this combination is safe and effective for participants with Immunoglobulin (Ig) M monoclonal gammopathy of undetermined significance ( IgM MGUS) or Waldenström macroglobulinemia WM related neuropathies. The names of the study drugs involved in this study are/is: - Acalabrutinib - Rituximab or similar CD20 antibody Type: Interventional Start Date: Nov 2021 |
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
Massachusetts General Hospital
Metastatic Urothelial Carcinoma
Bladder Cancer
This research study is examining the effectiveness of pembrolizumab plus cryoablation or
aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer,
that has spread. expand
This research study is examining the effectiveness of pembrolizumab plus cryoablation or aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer, that has spread. Type: Interventional Start Date: Jun 2021 |
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
Kiniksa Pharmaceuticals (UK), Ltd.
Recurrent Pericarditis
The registry will focus on furthering the understanding of the natural history of
recurrent pericarditis (RP), as well as document RP-related clinical, health-related
quality of life (HRQoL), and economic burden and will assist the medical community to
refine or develop data-driven recommendations... expand
The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population. Type: Observational [Patient Registry] Start Date: Mar 2021 |
Strengthening of the First Dorsal Interosseous for Thumb Carpometacarpal Osteoarthritis
Massachusetts General Hospital
Thumb Osteoarthritis
First Dorsal Interosseous Strengthening
To determine the effect of first dorsal interosseus (FDI) strengthening in patients with
thumb carpometacarpal (CMC) osteoarthritis. expand
To determine the effect of first dorsal interosseus (FDI) strengthening in patients with thumb carpometacarpal (CMC) osteoarthritis. Type: Interventional Start Date: Dec 2016 |
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or...
National Cancer Institute (NCI)
Stage IB Lung Non-Small Cell Carcinoma AJCC v7
Stage II Lung Non-Small Cell Cancer AJCC v7
Stage IIA Lung Cancer AJCC v8
Stage IIB Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA
non-small cell lung cancer that has been or will be removed by surgery. Studying the
genes in a patient's tumor cells may help doctors select the best treatment for patients
that have certain genetic changes. expand
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes. Type: Interventional Start Date: Sep 2014 |
Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD
Massachusetts General Hospital
Subjective Cognitive Concerns
Mild Cognitive Impairment
Mild Behavioral Impairment
Healthy Aging
The goal of this study is to objectively test one's sense of smell, called olfaction, in
participants with Subjective Cognitive Concerns (SCC), Mild Cognitive Impairment, Mild
Behavioral Impairment (MBI), and age-matched controls. The main question it aims to
answer is whether the AROMHA Brain Health... expand
The goal of this study is to objectively test one's sense of smell, called olfaction, in participants with Subjective Cognitive Concerns (SCC), Mild Cognitive Impairment, Mild Behavioral Impairment (MBI), and age-matched controls. The main question it aims to answer is whether the AROMHA Brain Health Test could serve as a predictive biomarker of neurodegenerative disorders. This understanding will aid in the development of a noninvasive, cost-effective diagnostic tool that reliably and specifically distinguishes disease and normal aging populations. Participants will take the approximately 45-minute AROMHA Brain Health Smell Test where they will peel and sniff labels on the physical smell cards and answer questions on the web-based app relating to what they smelled. Participants will undergo tests for odor intensity, odor identification, odor discrimination, and episodic olfactory memory, but will not be provided the results of these tests. Type: Observational Start Date: May 2023 |
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
Massachusetts General Hospital
Schwannomatosis
Schwannomas
Pain, Chronic
This is a placebo-controlled, multi-arm phase II platform screening trial designed to
test the safety, pain responses, and pharmacodynamic activity of multiple experimental
therapies simultaneously in participants with moderate-to-severe pain due to
schwannomatosis (SWN).
This Master Study is being... expand
This is a placebo-controlled, multi-arm phase II platform screening trial designed to test the safety, pain responses, and pharmacodynamic activity of multiple experimental therapies simultaneously in participants with moderate-to-severe pain due to schwannomatosis (SWN). This Master Study is being conducted as a platform that may allow participants with pain associated with schwannomatosis to receive a novel intervention throughout this study. Embedded within the Master Study are individual drug sub-studies: - Investigational Drug Sub-Study A: Siltuximab - Investigation Drug Sub-Study B: Erenumab-Aooe Type: Interventional Start Date: Aug 2023 |
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Werewolf Therapeutics, Inc.
Advanced or Metastatic Solid Tumors
Non-Hodgkin Lymphoma
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a
monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma. expand
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma. Type: Interventional Start Date: Dec 2022 |
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
Massachusetts General Hospital
Anosmia
Asymptomatic COVID-19
COVID-19 Respiratory Infection
Influenza
Healthy
The purpose of this study is to learn more about how to better track smell recovery in
people who have been infected with the SARS-CoV-2 virus (which causes COVID-19). Many
people who have been infected by this virus develop changes in their sense of smell
(olfaction). We are interested in measuring... expand
The purpose of this study is to learn more about how to better track smell recovery in people who have been infected with the SARS-CoV-2 virus (which causes COVID-19). Many people who have been infected by this virus develop changes in their sense of smell (olfaction). We are interested in measuring smell function objectively via smell cards that test odor intensity, identification, and discrimination. Objective and precise olfactory testing that can be performed in the convenience of one's home will help identify people with smell loss after infection by SARS-CoV-2. We will use results from this test to better understand the relationship between SARS-CoV-2 infection and recovery of olfactory function and to learn whether the AROMHA longitudinal smell test is a reliable olfactory function tracking tool to quantify smell loss in the context of COVID infection. These results may inform the design of therapeutic clinical trials to accelerate the recovery of smell function. Type: Observational [Patient Registry] Start Date: Nov 2022 |
The Wandering Nerve: Gateway to Boost Alzheimer's Disease Related Cognitive Performance
Massachusetts General Hospital
Aging
In this research study the investigators want to find out if a non-invasive electrical
brain stimulation method called RAVANS (also called tVNS) can have a beneficial effect on
cognition in older individuals. The investigators also want to understand whether certain
individual factors contribute to... expand
In this research study the investigators want to find out if a non-invasive electrical brain stimulation method called RAVANS (also called tVNS) can have a beneficial effect on cognition in older individuals. The investigators also want to understand whether certain individual factors contribute to the effect of RAVANS on cognition. RAVANS is only used in research studies. Type: Interventional Start Date: Nov 2021 |
A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018
Regeneron Pharmaceuticals
Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Endometrial Cancer
This study is researching an investigational drug called REGN5668. Participants will
receive additional investigational drugs in combination with REGN5668. These additional
drugs include cemiplimab or REGN4018 (with or without sarilumab).
The main purposes of this study are to:
- Learn about... expand
This study is researching an investigational drug called REGN5668. Participants will receive additional investigational drugs in combination with REGN5668. These additional drugs include cemiplimab or REGN4018 (with or without sarilumab). The main purposes of this study are to: - Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus - Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus This study has 2 parts. The purpose of Part 1 (Escalation) to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2. The study is looking at several other research questions, including: - Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab or REGN4018 - How REGN5668 works in the body either alone and/or in combination with cemiplimab or REGN4018 - How much of the study drugs (REGN5668, cemiplimab, REGN4018) are in the blood - To see if REGN5668 in combination with cemiplimab or REGN4018 works to treat cancer - To find out how safe, tolerable, and effective in mitigating Cytokine Release Syndrome (CRS) sarilumab pretreatment is when given before REGN4018 Type: Interventional Start Date: Dec 2020 |
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
Dana-Farber Cancer Institute
Li-Fraumeni Syndrome
TP53 Gene Mutation
Hereditary Cancer Syndrome
Clonal Hematopoiesis
Mosaicism
The purpose of this research study is to learn more about variants in the TP53 gene both
associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53
variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism). expand
The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism). Type: Observational [Patient Registry] Start Date: Sep 2020 |
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
Massachusetts General Hospital
Vulvar Cancer
Vulvar Squamous Cell Carcinoma
This research is being done to see how well the combination of a standard of care drug,
investigational drug, and radiation therapy work against unresectable vulvar squamous
cell carcinoma.
This research study involves the following:
- Cisplatin (standard of care drug)
- Pembrolizumab... expand
This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: - Cisplatin (standard of care drug) - Pembrolizumab (investigational drug) - Radiation Therapy (standard of care intervention) Type: Interventional Start Date: Jul 2020 |
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Mayo Clinic
Frontotemporal Lobar Degeneration (FTLD)
Progressive Supranuclear Palsy (PSP)
Corticobasal Degeneration (CBD)
Behavioral Variant Frontotemporal Dementia (bvFTD)
Semantic Variant Primary Progressive Aphasia (svPPA)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the
formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01
AG045390; funded through 2019) as a single North American research consortium to study
FTLD for 2019 and beyond. expand
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond. Type: Observational Start Date: Mar 2020 |
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Immunocore Ltd
Select Advanced Solid Tumors
IMC-F106C is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®)
designed for the treatment of cancers positive for the tumor-associated antigen PRAME.
This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C
in adult patients who have the appropriate... expand
IMC-F106C is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME. Type: Interventional Start Date: Feb 2020 |
Neuromodulation of Executive Function in the ADHD Brain
Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder
This study aims to determine the transient, modulatory effects of transcranial direct
current stimulation (tDCS) on executive function and inhibitory control in patients with
ADHD compared to healthy controls. expand
This study aims to determine the transient, modulatory effects of transcranial direct current stimulation (tDCS) on executive function and inhibitory control in patients with ADHD compared to healthy controls. Type: Interventional Start Date: Sep 2014 |
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness...
LivaNova
Treatment Resistant Depression
Objectives of this study are to determine whether active VNS Therapy treatment is
superior to a no stimulation control in producing a reduction in baseline depressive
symptom severity, based on multiple depression scale assessment tools at 12 months from
randomization. expand
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization. Type: Interventional Start Date: Sep 2019 |
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid...
Loxo Oncology, Inc.
Non-Small Cell Lung Cancer
Medullary Thyroid Cancer
Colon Cancer
Any Solid Tumor
This is an open-label, first-in-human study designed to evaluate the safety,
tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib
(also known as LOXO-292) administered orally to participants with advanced solid tumors,
including rearranged during transfection (RET)-fusion-positive... expand
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation. Type: Interventional Start Date: May 2017 |
Metastatic Tumor Research and Outcomes Network
AO Innovation Translation Center
Metastatic Spine Tumor
The registry aims to collect patient information such as patient demographics,
co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on
adverse events and HRQOL outcomes specific for patients with metastatic spine tumor(s). expand
The registry aims to collect patient information such as patient demographics, co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on adverse events and HRQOL outcomes specific for patients with metastatic spine tumor(s). Type: Observational [Patient Registry] Start Date: Nov 2017 |
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Lumicell, Inc.
Colorectal Cancer
Pancreatic Cancer
Esophageal Cancer
Gastric Cancer
The overall goal of this feasibility study is to assess the initial safety and efficacy
of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers
(adenocarcinoma) using the LUM Imaging System. expand
The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System. Type: Interventional Start Date: Aug 2016 |
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Erasmus Medical Center
Glioblastoma, IDH-wildtype
Glioblastoma
Glioblastoma Multiforme of Brain
Astrocytoma, Malignant
Brain Neoplasms
Resection of glioblastoma in or near functional brain tissue is challenging because of
the proximity of important structures to the tumor site. To pursue maximal resection in a
safe manner, mapping methods have been developed to test for motor and language function
during the operation. Previous evidence... expand
Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site. To pursue maximal resection in a safe manner, mapping methods have been developed to test for motor and language function during the operation. Previous evidence suggests that these techniques are beneficial for maximum safe resection in newly diagnosed grade 2-4 astrocytoma, grade 2-3 oligodendroglioma, and recently, glioblastoma. However, their effects in recurrent glioblastoma are still poorly understood. The aim of this study, therefore, is to compare the effects of awake mapping and asleep mapping with no mapping in resections for recurrent glioblastoma. This study is an international, multicenter, prospective 3-arm cohort study of observational nature. Recurrent glioblastoma patients will be operated with mapping or no mapping techniques with a 1:1 ratio. Primary endpoints are: 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months, and 6 months after surgery and 2) residual tumor volume of the contrast-enhancing and non-contrast-enhancing part as assessed by a neuroradiologist on postoperative contrast MRI scans. Secondary endpoints are: 1) overall survival (OS), 2) progression-free survival (PFS), 4) health-related quality of life (HRQoL) at 6 weeks, 3 months, and 6 months after surgery, and 4) frequency and severity of Serious Adverse Events (SAEs) in each arm. Estimated total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year. The study will be carried out by the centers affiliated with the European and North American Consortium and Registry for Intraoperative Mapping (ENCRAM). Type: Observational Start Date: Jan 2023 |
- Previous
- Next